United Therapeutics Corporation
United Therapeutics Corporation/ US91307C1027 /
UTHR
|
2024-05-10 10:00:00 PM
|
Chg.
-1.7800
|
Volume |
Bid12:00:01 AM |
Ask12:00:01 AM |
Market Capitalization |
Dividend Y. |
P/E Ratio |
|
264.2700USD
|
-0.67%
|
391,702
Turnover: 61.28 mill. |
220.0000Bid Size: 100 |
274.8300Ask Size: 100 |
11.72 bill.USD |
- |
12.56 |
Business description
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of innovative products to address the unmet medical needs of patients with chronic and life-threatening cardiovascular and infectious diseases and cancer.
Management board & Supervisory board
| CEO |
| Dr. Martine A. Rothblatt |
| Management board |
| James C. Edgemond, Michael Benkowitz, Paul A. Mahon |
| Supervisory board |
| Dr. Martine A. Rothblatt, Christopher Causey, Christopher Patusky, Dr. Judy D. Olian, Dr. Katherine J. Klein, Linda Maxwell, M.D., Louis Sullivan, Nilda Mesa, Prof. Raymond Dwek, Ray Kurzweil, Richard Giltner, Tommy G. Thompson |
Company data
| Name: |
United Therapeutics Corporation |
| Address: |
1040 Spring Street,Silver Spring, Maryland 20910, USA |
| Phone: |
+1-301-608-9292 |
| Fax: |
+1-301-608-9291 |
| E-mail: |
-
|
| Internet: |
is.gd/1hUSaA |
| Industry: |
Biotechnology |
| Sector: |
Biotechnology |
| Sub sector: |
Biotechnology |
| End of financial year: |
12-31 |
| Free Float: |
61.80% |
| IPO date: |
- |
Investor relations
| Name: |
- |
| IR phone: |
- |
| IR Fax: |
- |
| IR e-mail: |
ir@unither.com
|
Main Shareholders
| Freefloat |
|
61.80% |
| BlackRock, Inc |
|
9.60% |
| The Vanguard Group |
|
8.90% |
| Renaissance Technologies LLC |
|
8.10% |
| Avoro Capital Advisors LLC |
|
6.40% |
| FMR, LLC |
|
5.20% |
